GlassScriptPhysician profile
Eriks A Usis
NPI 1982601324
$7,408.21
in general payments reported to CMS, 2019-2025
25 companies · $514 in 2025
The $514 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,988 · 2020: $133 · 2021: $320 · 2022: $394 · 2023: $476 · 2024: $584 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $5,358.06 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $481.53 | 2019-2025 | |
| Corium, LLC | $293.88 | 2023-2025 | Azstarys, Azstarys |
| Merck Sharp & Dohme LLC | $167.14 | 2020-2025 | Rotateq, Gardasil 9, Vaxneuvance |
| Sobi, INC | $130.16 | 2019-2024 | |
| Glaxosmithkline, LLC. | $129.10 | 2019-2025 | Bexsero |
| Phadia US INC. | $107.61 | 2021-2025 | Immunocap |
| Cranial Technologies, INC | $101.04 | 2019-2025 | Doc Band |
| Genentech USA, INC. | $90.80 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $87.54 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $60.04 | 2021-2022 | |
| Sanofi Pasteur INC. | $56.07 | 2023-2024 | |
| Shire North American Group INC | $54.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.10 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $38.76 | 2024-2025 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $33.33 | 2025 | Bylvay |
| Kowa Pharmaceuticals America, INC. | $31.40 | 2025 | Zoryve |
| Kaleo, INC. | $24.11 | 2019-2023 | Auvi-Q |
| Biomarin Pharmaceutical INC. | $21.09 | 2025 | Voxzogo 1.2mg |
| Springworks Therapeutics, INC. | $20.12 | 2025 | Gomekli |
| Azurity Pharmaceuticals, INC. | $20.12 | 2025 | Alvesco |
| Biogen, INC. | $18.98 | 2024 | Spinraza |
| Seqirus USA INC | $15.71 | 2023 | Flucelvax Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $13.66 | 2025 | Neffy |
| Mission Pharmacal Company | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eriks Usis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.